Paid

Drugs & Targets

CHMP issues positive opinions for Imbruvica and Afinitor

The European Medicines Agency Committee for Medicinal Products for Human Use issued a positive opinion for Imbruvica (ibrutinib) for the treatment of adult patients with previously-untreated chronic lymphocytic leukemia. The positive CHMP recommendation follows the March 2016 FDA approval of Imbruvica for the first-line treatment of patients with CLL. If approved by the European Commission,... […]
Drugs & Targets

Health Canada approves Lynparza in ovarian cancer

Health Canada approved Lynparza (olaparib) capsules as a maintenance treatment for patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer. Lynparza is the first poly ADP-ribose polymerase inhibitor available in Canada, and has been granted the Health Canada Notice of Compliance with Conditions, based on... […]
In Brief

Sean Parker recognized by the Vatican for philanthropic work

SEAN PARKER received the Pontifical Key Philanthropy Award at the Vatican, presented by Cardinal Gianfranco Ravasi, president of the Pontifical Council for Culture, and Robin Smith, president of the Stem for Life Foundation. This recognition was announced during The Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact, held in Vatican... […]